Catalog No.
RHE84607
Species reactivity
Human, Rat
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, WB: 1:500-1:2000
Target
GPC3, MXR7, GTR2-2, Glypican-3, Intestinal protein OCI-5, OCI5
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P51654
Applications
ELISA, FCM, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3M58
Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor., PMID:40433120
Structural Features of Glypicans and their Impact on Wnt Signaling in Cancer., PMID:40416340
Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells., PMID:40307410
Dual-antibody functionalized transistor biosensor for specific diagnosis of liver cancer., PMID:40203597
Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients., PMID:40076777
Targeting glypican 3 by immunotoxins: the promise of immunotherapy in hepatocellular carcinoma., PMID:39985417
Anti-GPC3 antibody and cell-penetrating peptide CPP44 dual-ligand modified liposomes for targeted delivery of arsenic trioxide in the treatment of hepatocellular carcinoma., PMID:39883090
Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression., PMID:39838375
A proteomic atlas of glypican-3 interacting partners: Identification of alpha-fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancer., PMID:39822733
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma., PMID:39815170
GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target., PMID:39725192
Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy., PMID:39428649
The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential., PMID:39369212
The Inhibitory Effects of Anti-GPC3 Antibody on Wnt/β-Catenin Signaling Pathway as a Biological Therapy in Liver Cancer., PMID:39349719
Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma., PMID:39312187
Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation., PMID:39113871
[Preparation of bacterial outer membrane vesicles with anti-GPC3 single-chain antibody and identification of their targeting effects on hepatocellular carcinoma]., PMID:39044589
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors., PMID:39043602
Ultrasound-Responsive Nanodelivery System of GPC3-Targeting and Sonosensitizer for Visualized Hepatocellular Carcinoma Therapy., PMID:39011387
Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma., PMID:38978570
A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding., PMID:38776682
Extraction-free, immuno-RPA-CRISPR/Cas13a-based one-pot detection of glypican-3 directly from extracellular vesicles., PMID:38438232
Current methods for the detection of glypican-3., PMID:38108085
Exosomes with IR780 and Lenvatinib loaded on GPC3 single-chain scFv antibodies for targeted hyperthermia and chemotherapy in hepatocellular carcinoma therapy., PMID:38058824
A Single-Step Immunocapture Assay to Quantify HCC Exosomes Using the Highly Sensitive Fluorescence Nanoparticle-Tracking Analysis., PMID:37936599
Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood., PMID:37636242
Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH., PMID:37626430
Prognostic value of S100A4 and Glypican-3 in hepatocellular carcinoma in cirrhotic HCV patients., PMID:37599312
Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy., PMID:37478283
Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma., PMID:37103671
Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3., PMID:37048069
Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET., PMID:36997331
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody., PMID:36990507
H-rGO-Pd NPs Nanozyme Enhanced Silver Deposition Strategy for Electrochemical Detection of Glypican-3., PMID:36903516
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC., PMID:36691969
A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma., PMID:36681851
Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma., PMID:36640111
Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma., PMID:36524206
IL-2/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K/AKT and ERK1/2 pathways., PMID:36474002
Nanobody-based CAR T cells targeting intracellular tumor antigens., PMID:36411612
Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma., PMID:36375323
GPC3-Unc5 receptor complex structure and role in cell migration., PMID:36240740
Ruthenium-Based Metal-Organic Nanoradiosensitizers Enhance Radiotherapy by Combining ROS Generation and CO Gas Release., PMID:36184566
Impaired Autophagy Response in Hepatocellular Carcinomas Enriches Glypican-3 in Exosomes, Not in the Microvesicles., PMID:36105695
Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma., PMID:36072763
A New Combination: Anti Glypican-3 scFv and Diphtheria Toxin with the Best Flexible Linker., PMID:36001255
Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances., PMID:35961708
Frequently expressed glypican-3 as a promising novel therapeutic target for osteosarcomas., PMID:35946078
Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma., PMID:35937502
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma., PMID:35739268
For research use only. Not for human or drug use.
